^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Hervelous (trastuzumab biosimilar) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
Published date:
05/01/2022
Excerpt:
This randomized clinical trial (TROIKA) included 502 women with ERBB2-positive early breast cancer treated with either HD201 or referent trastuzumab....The tpCR rates were 45% and 48.7% for HD201 and referent trastuzumab, respectively....The results of this randomized clinical trial found that HD201 demonstrated equivalence to referent trastuzumab in terms of efficacy for the end point of tpCR, with a similar safety profile.
DOI:
10.1001/jamaoncol.2021.8171
Trial ID:
Source:
Title:
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
Published date:
03/03/2022
Excerpt:
Patients with ERBB2-positive early breast cancer were randomly assigned to receive HD201...The tpCR rates were 45% and 48.7% for HD201 and referent trastuzumab, respectively….The results of this randomized clinical trial found that HD201 demonstrated equivalence to referent trastuzumab in terms of efficacy for the end point of tpCR, with a similar safety profile.
DOI:
10.1001/jamaoncol.2021.8171
